London-based biotech Briefly Bio, which improves communication in experimental science, has secured $1.2 million in a pre-seed funding round led by Compound, with participation from NP Hard, Tiny VC, and several angel investors. The investment will help Briefly Bio further commercialize its software.
- Founded in 2022 by Harrison Rickerby, Staffan Piledahl, and Katya Putintseva, Briefly Bio develops a platform aimed at making biological science more reproducible across industry and academia. The tool enables the capture and sharing of lab work in a clear and consistent manner.
- The platform automatically transforms text into a concise protocol format, leveraging AI Copilot to identify missing details and propose improvements. It facilitates drafting, material extraction, and linking methods to calculations, enabling step-by-step experiment design. Additionally, it offers a collaborative workspace for team interaction.
“Some of our users rely on Briefly to align on experimental design within their teams. Others use it to communicate wet-lab protocols to automation engineers. And some use it to share cocktail recipes,” Co-founder at Briefly Bio, Katya Putintseva, stated.
Details of the deal
- The fresh funding round was led by Compound, an investment management firm overseeing $2 billion in assets. Additionally, NP Hard, London-based Tiny VC, and several angel investors participated in the funding.
- The capital raised will allow Briefly Bio to launch its platform for commercial use, aiming to enhance the reproducibility of biological science in both industry and academia.
